Intra-Cellular Therapies (ITCI) PT Raised to $65 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Ami Fadia raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $65.00 (from $59.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
